Global Pneumococcal Vaccine Market Growth, Size, Trends Analysis - By Vaccine Type, By Product, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Pneumococcal Vaccine Market Introduction and Overview

According to SPER market research, 'Global Pneumococcal Vaccine Market Size- By Vaccine Type, By Product, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' states that the Global Pneumococcal Vaccine Market is predicted to reach 16.02 billion by 2034 with a CAGR of 6.43%.

The bacteria that cause pneumonia, meningitis, and bloodstream infections is Streptococcus pneumoniae. The goal of pneumococcal vaccinations is to shield against infections caused by this pathogen. These vaccines work by stimulating the immune system to recognize and respond to specific pneumococcal serotypes. Pneumococcal conjugate vaccines (PCVs), which provide strong and long-lasting immunity to infants and young children, and pneumococcal polysaccharide vaccines (PPSVs), which are primarily used for high-risk populations and older adults, are the two main types that are frequently used.

Restraints: There are several challenges facing the pneumococcal vaccine market that restrict its expansion and accessibility. The constant emergence of new serotypes that are not covered by existing formulations necessitates ongoing research and development, which drives up costs. High production costs and intricate manufacturing processes limit affordability for low- and middle-income countries. Price competition in public tenders puts pressure on margins, but differences in national vaccination protocols and regulatory requirements may delay the adoption of products.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Vaccine Type, By Product, By End Use

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Serum Institute of India Pvt. Ltd., CSL

Sanofi, GSK plc, Merck & Co., Inc., Pfizer Inc., Walvax Biotechnology Co., Ltd

Beijing Minhai Biotechnology Co., Ltd

Global Pneumococcal Vaccine Market Segmentation:

By Vaccine Type: Based on the Vaccine Type, Global Pneumococcal Vaccine Market is segmented as; Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine.

By Product: Based on the Product, Global Pneumococcal Vaccine Market is segmented as; Prevnar 13, Synflorix, Pneumovax 23, VAXNEUVANCE, PNEUMOSIL.

By End User: Based on the End User, Global Pneumococcal Vaccine Market is segmented as; Public Sector, Private Sector.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25314

1.Introduction

1.1.Scope of the report
1.2.Market segment analysis

2.Research Methodology

2.1.Research data source
- 2.1.1.Secondary Data
- 2.1.2.Primary Data
- 2.1.3.SPERs internal database
- 2.1.4.Premium insight from KOLs
2.2.Market size estimation
- 2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

4.1.Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1.Drivers
- 4.1.2.Restraints
- 4.1.3.Opportunities
- 4.1.4.Challenges

5.Market variable and outlook

5.1.SWOT Analysis
- 5.1.1.Strengths
- 5.1.2.Weaknesses
- 5.1.3.Opportunities
- 5.1.4.Threats
5.2.PESTEL Analysis
- 5.2.1.Political Landscape
- 5.2.2.Economic Landscape
- 5.2.3.Social Landscape
- 5.2.4.Technological Landscape
- 5.2.5.Environmental Landscape
- 5.2.6.Legal Landscape
5.3.PORTERs Five Forces
- 5.3.1.Bargaining power of suppliers
- 5.3.2.Bargaining power of buyers
- 5.3.3.Threat of Substitute
- 5.3.4.Threat of new entrant
- 5.3.5.Competitive rivalry
5.4.Heat Map Analysis

6.Competitive Landscape

6.1.Global Pneumococcal Vaccine Market Manufacturing Base Distribution, Sales Area, Product Type
6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Pneumococcal Vaccine Market

7.Global Pneumococcal Vaccine Market, By Vaccine Type (USD Million) 2021-2034

7.1.Pneumococcal Conjugate Vaccine
7.2.Pneumococcal Polysaccharide Vaccine

8.Global Pneumococcal Vaccine Market, By Product (USD Million) 2021-2034

8.1.Prevnar 13
8.2.Synflorix
8.3.Pneumovax 23
8.4.VAXNEUVANCE
8.5.PNEUMOSIL
8.6.Other Products

9.Global Pneumococcal Vaccine Market, By End User (USD Million) 2021-2034

9.1.Public Sector
9.2.Private Sector

10.Global Pneumococcal Vaccine Market, (USD Million) 2021-2034

10.1.Global Pneumococcal Vaccine Market Size and Market Share

11.Global Pneumococcal Vaccine Market, By Region, (USD Million) 2021-2034

11.1.Asia-Pacific
- 11.1.1.Australia
- 11.1.2.China
- 11.1.3.India
- 11.1.4.Japan
- 11.1.5.South Korea
- 11.1.6.Rest of Asia-Pacific
11.2.Europe
- 11.2.1.France
- 11.2.2.Germany
- 11.2.3.Italy
- 11.2.4.Spain
- 11.2.5.United Kingdom
- 11.2.6.Rest of Europe
11.3.Middle East and Africa
- 11.3.1.Kingdom of Saudi Arabia
- 11.3.2.United Arab Emirates
- 11.3.3.Qatar
- 11.3.4.South Africa
- 11.3.5.Egypt
- 11.3.6.Morocco
- 11.3.7.Nigeria
- 11.3.8.Rest of Middle-East and Africa
11.4.North America
- 11.4.1.Canada
- 11.4.2.Mexico
- 11.4.3.United States
11.5.Latin America
- 11.5.1.Argentina
- 11.5.2.Brazil
- 11.5.3.Rest of Latin America

12.Company Profile

12.1.Serum Institute of India Pvt. Ltd
- 12.1.1.Company details
- 12.1.2.Financial outlook
- 12.1.3.Product summary
- 12.1.4.Recent developments
12.2.CSL
- 12.2.1.Company details
- 12.2.2.Financial outlook
- 12.2.3.Product summary
- 12.2.4.Recent developments
12.3.Sanofi
- 12.3.1.Company details
- 12.3.2.Financial outlook
- 12.3.3.Product summary
- 12.3.4.Recent developments
12.4.GSK plc
- 12.4.1.Company details
- 12.4.2.Financial outlook
- 12.4.3.Product summary
- 12.4.4.Recent developments
12.5.Merck & Co., Inc
- 12.5.1.Company details
- 12.5.2.Financial outlook
- 12.5.3.Product summary
- 12.5.4.Recent developments
12.6.Pfizer Inc
- 12.6.1.Company details
- 12.6.2.Financial outlook
- 12.6.3.Product summary
- 12.6.4.Recent developments
12.7.Walvax Biotechnology Co., Ltd
- 12.7.1.Company details
- 12.7.2.Financial outlook
- 12.7.3.Product summary
- 12.7.4.Recent developments
12.8.Beijing Minhai Biotechnology Co., Ltd
- 12.8.1.Company details
- 12.8.2.Financial outlook
- 12.8.3.Product summary
- 12.8.4.Recent developments
12.9.Others